Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine 3-Dose Regimen Efficacy Study
NCT04966871Phase 1Completed
- Sponsor
- Sanaria Inc.
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sanaria PfSPZ Vaccine in Plasmodium falciparum malaria (6 arms), sponsored by Sanaria Inc. Primary endpoints: Vaccine Efficacy, Safety and Tolerability (Solicited Adverse Events) and 2 more. Started Sep 2021; status: completed.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT04966871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966871.